Pyxis Oncology Statistics
Total Valuation
Pyxis Oncology has a market cap or net worth of $249.97 million. The enterprise value is $154.02 million.
Market Cap | 249.97M |
Enterprise Value | 154.02M |
Important Dates
The next estimated earnings date is Thursday, May 9, 2024, before market open.
Earnings Date | May 9, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Pyxis Oncology has 58.13 million shares outstanding. The number of shares has increased by 20.80% in one year.
Shares Outstanding | 58.13M |
Shares Change (YoY) | +20.80% |
Shares Change (QoQ) | +7.62% |
Owned by Insiders (%) | 20.49% |
Owned by Institutions (%) | 29.90% |
Float | 35.41M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | 55.21 |
PB Ratio | 2.02 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.84, with a Debt / Equity ratio of 0.17.
Current Ratio | 4.84 |
Quick Ratio | n/a |
Debt / Equity | 0.17 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -52.60% and return on invested capital (ROIC) is -55.90%.
Return on Equity (ROE) | -52.60% |
Return on Assets (ROA) | -41.10% |
Return on Capital (ROIC) | -55.90% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.48M |
Employee Count | 50 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +42.38% in the last 52 weeks. The beta is 1.51, so Pyxis Oncology's price volatility has been higher than the market average.
Beta (1Y) | 1.51 |
52-Week Price Change | +42.38% |
50-Day Moving Average | 5.14 |
200-Day Moving Average | 2.94 |
Relative Strength Index (RSI) | 42.52 |
Average Volume (30 Days) | 805,246 |
Short Selling Information
The latest short interest is 2.21 million, so 3.80% of the outstanding shares have been sold short.
Short Interest | 2.21M |
Short Previous Month | 2.70M |
Short % of Shares Out | 3.80% |
Short % of Float | 6.24% |
Short Ratio (days to cover) | 2.52 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -82.20M |
Pretax Income | -73.79M |
Net Income | -73.79M |
EBITDA | -71.20M |
EBIT | -73.79M |
Earnings Per Share (EPS) | -$1.85 |
Balance Sheet
The company has $120.77 million in cash and $21.33 million in debt, giving a net cash position of $99.44 million or $1.71 per share.
Cash & Cash Equivalents | 120.77M |
Total Debt | 21.33M |
Net Cash | 99.44M |
Net Cash Per Share | $1.71 |
Equity / Book Value | 125.70M |
Book Value Per Share | 2.16 |
Working Capital | 98.85M |
Cash Flow
In the last 12 months, operating cash flow was -$70.71 million and capital expenditures -$6.73 million, giving a free cash flow of -$77.44 million.
Operating Cash Flow | -70.71M |
Capital Expenditures | -6.73M |
Free Cash Flow | -77.44M |
FCF Per Share | -$1.94 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Pyxis Oncology does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -20.80% |
Shareholder Yield | -20.80% |
Earnings Yield | -29.11% |
FCF Yield | -30.55% |
Analyst Forecast
The average price target for Pyxis Oncology is $9.80, which is 126.85% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $9.80 |
Price Target Difference | 126.85% |
Analyst Consensus | Strong Buy |
Analyst Count | 5 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -2.72% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |